




The relative strengths and weaknesses of Moleculin Biotech Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Moleculin Biotech Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 166% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 88% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	9,686
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,854
Liabilities, Non-Current	222
Other Assets	12,362
Other Compr. Net Income	51
Other Expenses	-22,944
Other Liabilities	44
Other Net Income	-31,491
Other Revenues	0
Property and Equipment	78
Research and Development	15,891
Selling, General and Administrative Expense	9,122

Output Variable	Value in 1000 USD
Assets	22,126
Liabilities	7,120
Expenses	2,069
Revenues	0
Stockholders Equity	15,006
Net Income	-33,560
Comprehensive Net Income	-33,534
BaseVar	31,428
ECR before LimitedLiability	-5.6%
Economic Capital Ratio	141%